drugset / Trial / NCT07290036
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
RandomizedParallel-groupOpen-labelTreatment
Summary
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Timeline
- Start
- 2025-12-10
- Primary completion
- 2028-05-18
- Completion
- 2028-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimekizumab | Monoclonal antibody | — | Intravenous |